LIM激酶及其抑制剂的研究进展  

Research progresses of LIMK/cofilin signal pathway and its inhibitors

作　　者：黄启璐 吴爱兵 杨志雄 HUANG Qi-lu;WU Ai-bing;YANG Zhi-xiong(Department of Oncology,the Affiliated Hospital of Guangdong Medical University,Zhanjiang 524000,Guangdong,CHINA)

机构地区：[1]广东医科大学附属医院肿瘤中心,广东湛江524000

出　　处：《海南医学》2020年第10期1317-1320,共4页Hainan Medical Journal

摘　　要：LIM激酶是一种存在于真核生物中的丝氨酸/苏氨酸蛋白激酶,主要包括LIMK1及LIMK2,而LIMKs是cofilin的磷酸酶,通过磷酸化cofilin的Ser3位点调控肌动蛋白动力学及微管解聚,参与细胞的增殖及运动。目前研究发现LIMKs在肿瘤组织及细胞中呈高表达,参与了肿瘤的发生发展,针对LIM激酶的抑制剂也在不断的开发中。除了癌症的治疗,LIM激酶抑制剂也在其他疾病中进行研究。The LIM kinase family, a serine/threonine protein kinase present in eukaryotes, mainly includes LIMK1 and LIMK2. LIMKs, as cofilin phosphatases, can regulate the dynamics of actin and microtubule by phosphorylating Ser3 of cofilin, and anticipate the proliferation and motion of cells. Currently, the research found that LIMKs are highly expressed in tumor tissues and cells, which participate the development of tumors. The inhibitors of the LIM kinase are also being developed. In addition, LIM kinase inhibitors are also researched in other diseases.

关 键 词：LIM激酶 丝切蛋白 LIMK/cofilin信号通路 肿瘤/癌症 LIMK抑制剂 

分 类 号：R329.28[医药卫生—人体解剖和组织胚胎学]